Digestive Diseases and Sciences

, Volume 47, Issue 10, pp 2192–2210

Lovastatin Alters Biliary Lipid Composition and Dissolves Gallstones: A Long-Term Study in Prairie Dogs

  • Mohammad Z. Abedin
  • Seth C. Narins
  • Eun H. Park
  • Peter R. Smith
  • Kimberly S. Kirkwood


Lovastatin, an inhibitor of the rate-limiting enzyme in cholesterol biosynthesis, is widely used to treat hypercholesterolemia. We investigated the long-term effects of lovastatin alone and in combination with ursodeoxycholic acid on biliary lipid composition and gallstone dissolution. Forty-two prairie dogs were fed 1.2% cholesterol diet for 5 weeks, and cholecystectomy was performed on 6 animals to confirm gallstones. The remaining animals were maintained on a 0.4% cholesterol diet and were randomized to receive placebo, lovastatin (3.3 mg/g diet), ursodeoxycholic acid (10 mg/g), or combination of both drugs. After 10 weeks, animals underwent cholecystectomy. Dissolution response to therapy was determined, and serum and biliary lipids were measured. All treatment groups had significant reductions in serum cholesterol. Lovastatin treatment reduced both hepatic and gallbladder bile cholesterol, altered bile acid composition, and induced a 79% total response compared to placebo. Although ursodeoxycholic treatment induced a 44% response, long-term combination treatment elevated both gallbladder bile cholesterol and calcium and failed to produce an augmented response. These data suggest that lovastatin therapy alone may promote gallstone dissolution in humans.

gallstones dissolution lovastatin cholesterol bile acids prairie dogs 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Diehl A: Epidemiology and natural history of gallstone disease. Gastroenterol Clin North Am 20:1–19, 1991Google Scholar
  2. 2.
    NIH CDP: Gallstones and laparoscopic cholecystectomy. JAMA 269(8):1018–1024, 1993Google Scholar
  3. 3.
    Lagergren J, Ye W, Ekbom A: Intestinal cancer after cholecystectomy: is bile involved in carcinogenesis? Gastroenterology 121:542–547, 2001Google Scholar
  4. 4.
    Freedman J, Ye W, Naaslund E, Lagergren J: Association between cholecystectomy and adenocarcinoma of the esophagus. Gastroenterology 121:548–553, 2001Google Scholar
  5. 5.
    Salen G, Colalillo A, Verga D, Bagan E, Tint GS, Shefer S: Effect of high and low doses of ursodeoxycholic acid on gallstone dissolution in humans. Gastroenterology 78:1412–1418, 1980Google Scholar
  6. 6.
    Shoenfield LJ, Lachin JM: The steering committee: chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of effi-cacy and safety. Ann Intern Med 95:257–282, 1981Google Scholar
  7. 7.
    Roda E, Bazzoli F, Labate AM, Mazzella G, Roda A, Sama C, Festi D, Aldini R, Taroni F, Barbara L: Ursodeoxycholic acid vs chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study. Hepatology 2:804–810, 1982Google Scholar
  8. 8.
    Admirand WH, Small DM: The physiochemical basis of cholesterol gallstone formation in man. J Clin Invest 47:1043–1052, 1968Google Scholar
  9. 9.
    Angelin B, Ewerth S, Einarsson K: Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliarynlipid composition and plasma lipid levels. J Lipid Res 24:461–468, 1983Google Scholar
  10. 10.
    Staffan S, Thyberg P, Ahlberg J, Angelin B, Einarsson K: Distribution of cholesterol between vesicles and micelles in human gallbladder bile: influence of treatment with chenodeoxycholic acid and ursodeoxycholic acid. Hepatology 13:104–110, 1991Google Scholar
  11. 11.
    Hofmann AF: Rationale of bile acid therapy after biliary lithotripsy. In Biliary Lithotripsy. JT Ferrucci, M Delius, HJ Burhenne (eds). Chicago, Year Book Mediacl Publishers, 1989, pp 151–157Google Scholar
  12. 12.
    Sackmann M, Delius M, Sauerbruch T, Holl J, Weber W, Ippisch E, Hagelauer U, Wess O, Hepp W, Brendel W: Shockwave lithotripsy of gallbladder stones–the first 175 patients. N Engl J Med 318:393–397, 1988Google Scholar
  13. 13.
    Erlinger S, Go AL, Husson JM, Fevery J: Franco-Belgian cooperative study of ursodeoxycholic acid in the medical dissolution of gallstones: a double-blind, randomized, doseresponse study, and comparison with chenodeoxycholic acid. Hepatology 4:308–314, 1984Google Scholar
  14. 14.
    Fromm H, Roat JW, Gonzalez V, Sarva RJ, Farivar S: Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones: a double blind controlled study. Gastroenterology 85:1257–1264, 1983Google Scholar
  15. 15.
    Bachrach WH, Hofmann AF: Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Dig Dis Sci 27:737–856, 1982Google Scholar
  16. 16.
    Alberts AW, Chen J, Kuron G, Hung V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albershonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J: Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutarylcoenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 77:3957–3961, 1980Google Scholar
  17. 17.
    Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, Tobert JA, Bacon SR, Bolognese JA, Frost PH, Lamkin GE: Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann Intern Med 107:609–615, 1987Google Scholar
  18. 18.
    Bilheimer DW: Long-term clinical tolerance of lovastatin and simvastatin. Cardiology 77:58–65, 1990Google Scholar
  19. 19.
    Pertsemlidis DE, Panveliwaila D, Ahrens AH Jr: Effects of clofibrate and an estrogen-progestin combination of fasting biliary lipids and cholic acid kinetics in man. Gastroenterology 66:565–573, 1974Google Scholar
  20. 20.
    The Coronary Drug Project Research Group CDP: Clofibrate and niacin in heart disease. JAMA 231:360–381, 1975Google Scholar
  21. 21.
    Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL: Simvastatin, a competive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology 8:1147–1150, 1988Google Scholar
  22. 22.
    Logan GM, Duane WC: Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation. Gastroenterology 98:1572–1576, 1990Google Scholar
  23. 23.
    Carulli N, Ponz de Leon M, Zironi F, Pinetti A, Smerieri A, Iori R, Loria P: Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short term feeding of chenodeoxycholic and ursodeoxycholic acid. J Lipid Res 21:35–43, 1980Google Scholar
  24. 24.
    Saunders KD, Cates JA, Abedin MZ, Rege S, Festekdjian SF, Howard W, Roslyn JJ: Lovastatin inhibits gallstone formation in the cholesterol-fed prairie dog. Ann Surg 214(2):149–154, 1991Google Scholar
  25. 25.
    Saunders KD, Cates JA, Abedin MZ, Roslyn JJ: Lovastatin and gallstone dissolution: a preliminary study. Surgery 113(1):28–35, 1993Google Scholar
  26. 26.
    Sackmann M, Koelble R, Pauletzki J, Cremer P, Kluppelberg UG, von Ritter C, Sauter G, Holl J, Siedel D, Paumgartner G: Simvastain added to ursodeoxycholic acid does not enhance disappearance of gallstone fragments after shockwave therapy. Z Gastroenterol 33:585–589, 1995Google Scholar
  27. 27.
    Glasonovic JC, Scrivanti M, Mege RM, Raddatz O, Alvarado A, Validivia MT, Ahumada E: Gallstone dissolution in an adult female population: trial with lovastatin therapy. Rev Med Chile 124(7):793–798, 1996Google Scholar
  28. 28.
    Tazuma S, Kajiyama G, Mizuno T, Yamashita G, Miura H, Kajihara T, Hattori Y, Miyake H, Nishioka T, Hyogo H, Sunami Y, Yasumiba S, Ochi H, Matsumoto T, Abe A, Adachi K, Omatta F, Ueno F, Ohguri S, Shibata H, Kokubu H: A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than ursodeoxycholic acid monotherapy. J Clin Gastroenterol 26:287–291, 1998Google Scholar
  29. 29.
    Gurll N, DenBesten L: Animal models of human cholesterol gallstone disease: a review. Lab Anim Sci 28(4):428–432, 1978Google Scholar
  30. 30.
    Holzbach RT: Animal models of cholesterol gallstone disease. Hepatology 4(5 suppl):191S–198S, 1984Google Scholar
  31. 31.
    Brenneman DE, Connor WE, Forker EL, DenBesten L: The formation of abnormal bile and cholesterol gallstones from dietary cholesterol in the prairie dog. J Clin Invest 51(6):1495–1503, 1972Google Scholar
  32. 32.
    DenBesten L, Safaie-Shirazi S, Connor WE, Bell S: Early changes in bile composition and gallstone formation induced by a high cholesterol diet in prairie dogs. Gastroenterology 66(5):1036–1045, 1974Google Scholar
  33. 33.
    Roschlau P, Bernt E, Gruber W: Cholesterol and esterified cholesterol. In Methods of Enzymatic Analysis, Vol 4. HU Bergmeyer (ed). New York, Academic Press, 1974, pp 1890–1893Google Scholar
  34. 34.
    Dryer RL, Tammes AR, Routh JI: The determination of phosphorus and phosphatase with N-phenyl-p-phenylene diamine. J Biol Chem 225:177–183, 1957Google Scholar
  35. 35.
    Iwata T, Yamasaki K: Enzymatic determination and TLC of bile acids in blood. J Biochem 56:424–431, 1964Google Scholar
  36. 36.
    Anderegg C, Flaschka H, Sallman R, Schwarzenback GM: Metallindikatoren IV. Ein auf erdkaliionen ansprechendes phtalien und seine analytische Verwendung. Helv Chim Acta 37:113–120, 1951Google Scholar
  37. 37.
    Connerty HV, Briggs AR: Determination of serum calcium by means of orthocresolphthalein complexone. Am J Clin Pathol 45(3):290–296, 1966Google Scholar
  38. 38.
    Carey MC: Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res 19(8):945–955, 1978Google Scholar
  39. 39.
    Nakayama F, Nakagaki M: Quantitative determination of bile acids in bile with reversed-phase high performance liquid chromatography. J Chromatogr 183:287–293, 1980Google Scholar
  40. 40.
    Abedin MZ, Strichartz SD, Festekdjian S, Roslyn JJ: Increased biliary calcium in cholesterol and pigment gallstone disease: the role of altered bile acid composition. Lipids 24(7):572–578, 1989Google Scholar
  41. 41.
    Radin NS: Extraction of tissue lipids with a solvent of low toxicity. Methods Enzymol 72:5–10, 1981Google Scholar
  42. 42.
    Roslyn JJ, Conter RL, Julian E, Abedin MZ: The role of dietary iron in pigment gallstone formation. Surgery 102:327–333, 1987Google Scholar
  43. 43.
    Strichartz SD, Abedin MZ, Abdou MS, Roslyn JJ: Increased biliary calcium in cholesterol gallstone formation. Am J Surg 155(1):131–137, 1988Google Scholar
  44. 44.
    Carey MC, Small DM: The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man. J Clin Invest 61(4):998–1026, 1978Google Scholar
  45. 45.
    Podda M, Zuin M, Battezzati PM, Ghezzi C, Fazio CD, Dioguardi ML: Efficacy and safety of a combination of chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution: a comparison with ursodeoxycholic acid alone. Gastroenterology 96:222–229, 1989Google Scholar
  46. 46.
    Park YH, Igimi H, Carey MC: Dissolution of human cholesterol gallstones in stimulated chenodeoxycholate-rich and ursodeoxycholate-rich biles. An in vitro study of dissolution rates and mechanisms. Gastroenterology 87(1):150–158, 1984Google Scholar
  47. 47.
    Corrigan OI, Su SC, Higuchi WI, Hofmann AF: Mesophase formation during cholesterol gallstone dissolution in ursodeoxycholate-lecithin solution: new mechanis for gallstone dissolution in humans. J Pharmacol Sci 69:869, 1980Google Scholar
  48. 48.
    Carey MC, Grace KO: The importance of total lipid concentration in determining cholesterol solubility in bile and the development of critical table for calculating percent cholesterol saturation with a correction factor for ursodeoxycholate-rich bile. In Biological Effects of Bile Acids. G Paumgartner, A Steihl, W Gerok (eds). Lancaster, England, MTP, 1979, pp 299–308Google Scholar
  49. 49.
    Stiehl A, Raedsch R, Czygan P, Gotz R, Manner CH, Walker S, Kommerel B: Effects of biliary bile acid composition on biliary cholesterol saturation in gallstone patients treated with chenodeoxycholic acid and/or ursodeoxycholic acid. Gastroenterology 79:1192–1198, 1980Google Scholar
  50. 50.
    Thomas PJ, Hofmann AF: A simple calculation of lithogenic index of bile: expressing biliary lipid composition on rectangular coordinates. Gastroenterology 65:898–700, 1973Google Scholar
  51. 51.
    Krukemeyer JJ, Talbert RL: Lovastatin: a new cholesterol lowering agent. Pharmacotherapy 7:198–210, 1987Google Scholar
  52. 52.
    Stone BG, Erickson SK, Craig WY, Cooper AD: Regulation of rat biliary cholesterol secretion by agents that alter intrahepatic cholesterol metabolism. J Clin Invest 76:1773–1781, 1985Google Scholar
  53. 53.
    Nilsell K, Angelin B, Leijd B, Finnarsson K: Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans: evidence for different modes of action on bile acid synthesis. Gastroenterology 85:1248–1256, 1983Google Scholar
  54. 54.
    von Bergmann K, Epple-Gusfeld M, Leiss O: Differences in the effects of chenodeoxycholic acid and ursodeoxycholic acid on biliary lipid secretion and bile acid synthesis in patients with gallstones. Gastroenterology 87:136–143, 1984Google Scholar
  55. 55.
    Leiss O, von Bergman K, Streicher V, Stotkoetter H: The effect of three different dihydroxy bile acids on intestinal cholesterol absorption in normal volunteers. Gastroenterology 87:144–149, 1984Google Scholar
  56. 56.
    Tint GS, Salen G, Shefer S: Effect of ursodeoxycholic and chenodeoxycholic acid on cholesterol and bile acid metabolism. Gastroenterology 91:1007–1018, 1986Google Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • Mohammad Z. Abedin
    • 1
  • Seth C. Narins
    • 1
  • Eun H. Park
    • 1
  • Peter R. Smith
    • 2
  • Kimberly S. Kirkwood
    • 3
  1. 1.Department of SurgeryMCP Hahnemann UniversityPhiladelphiaUSA
  2. 2.Department of Physiology and BiophysicsUniversity of Alabama at BirminghamBirminghamUSA
  3. 3.Department of General SurgeryUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations